Spun Out SPE's

In 2014, AskBio sold its special purpose entity (SPE), Chatham Therapeutics, which was focused on the use of AskBio’s AAV platform for the treatment of hemophilia, to Baxter Therapeutics.

Baxter Announces Exclusive Collaboration for Hemophilia B

Baxter to Acquire Chatham Therapeutics

In 2016, AskBio sold its special purpose entity, Bamboo Therapeutics, which was focused on the use of AskBio’s AAV platform technology for the treatment of Duchenne Muscular Dystrophy, to Pfizer.

Pfizer Aims to Become Industry Leader in Gene Therapy with Acquisition of Bamboo Therapeutics